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Abstract
Background: Only limited data are available regarding the diagnostic accuracy of fecal matrix 
metalloprotease-9 [MMP-9] for inflammatory bowel disease [IBD]. The aims of our study were 
to assess the diagnostic accuracy of fecal MMP-9 in patients with active Crohn’s disease [CD], 
ulcerative colitis [UC], and pouchitis, and to compare the diagnostic accuracy of fecal MMP-9 and 
fecal calprotectin [CP] in IBD.
Methods Stool and blood samples were collected in 50 CD, 54 UC, and 34 ileal pouch-anal 
anastomosis patients before control endoscopies were performed. Biopsies were taken for 
histologic purposes. The activities of CD, UC, and pouchitis were defined with the use of clinical, 
endoscopic, and histologic activity scores. Fecal CP and MMP-9 levels were quantified by enzyme-
linked immunosorbent assay.
Results Active CD, UC, and pouchitis were detected in 38%, 54%, and 29% of the patients, 
respectively. A significant correlation was revealed between fecal CP and the clinical activities of 
CD and UC, and between fecal CP and the endoscopic activity of UC and pouchitis. Fecal MMP-9 
did not correlate with any of the activity indices of CD; however, strong associations were shown 
between fecal MMP-9 and clinical, endoscopic, and histologic activities of both UC and pouchitis.
Conclusions This is the first study assessing the diagnostic accuracy of MMP-9 in different types 
of IBD. Our results showed that fecal MMP-9 has high sensitivity in the detection of endoscopically 
active UC and pouchitis. These non-invasive methods help assess intestinal inflammation.
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1. Background
The two main types of inflammatory bowel diseases [IBD]—Crohn’s 
disease [CD] and ulcerative colitis [UC]—are characterized by peri-
ods of remission and of relapse. Symptoms, laboratory parameters 
and the results of endoscopies and other imaging modalities are used 
in the assessment of disease activity. For monitoring the course and 
the activity of the disease and the response to different therapies, 
laboratory and fecal markers proved helpful; however, a biomarker 
that is absolutely specific to CD or UC has still not been developed. 
Intestinal inflammation, typical to both diseases, is associated with 
an acute-phase reaction with the migration of leukocytes to the 
affected area of the gut. The reason why fecal markers seem to be 
more specific to assess disease activity than laboratory markers in 
IBD is the fecal excretion of leukocytes, leukocyte products, and 
serum proteins.1 The most commonly used fecal activity marker is 
calprotectin [CP]. CP, derived predominately from neutrophils, can 
differentiate between active and inactive IBD and between IBD and 
irritable bowel syndrome [IBS]. It correlates with the severity of 
symptoms and may predict relapse—especially in the case of UC.2,3 
Finally, it can be used as a surrogate marker for the endoscopic 
response during treatment, given that a normal value of CP is a reli-
able marker for mucosal healing.4
Matrix metalloproteases [MMPs] are also released from the neu-
trophil secretory granules. MMP 1, 2, 3, and 9 have been detected 
in significantly higher levels in colonic biopsies of UC patients than 
in controls.5 MMP-9 has been shown to be significantly increased 
in the stool of UC patients compared with healthy controls and 
patients with IBS, and was found to correlate to a high degree with 
the clinical and endoscopic activity of UC, as well as with fecal CP.6 
A  recently published paper on pediatric patients also confirmed 
the efficacy of fecal MMP-9 in the separation of IBD and non-IBD 
patients.7 Since the role of this new fecal activity marker, MMP-9, 
has previously not been compared in different types of IBD, the aim 
of our prospective study was to assess the diagnostic accuracy of 
fecal MMP-9 in patients with active CD, UC, and pouchitis, assessed 
by clinical, endoscopic, and histologic scores, and to compare the 
diagnostic accuracy of fecal MMP-9 and fecal CP in IBD.
2.1 Patients and Methods
2.2. Study population
Overall, 50 CD (female/male ratio: 26/24; mean age at CD diag-
nosis: 30 years; disease location: ileal: 11, colonic: 15, ileocolonic: 
24, upper gastrointestinal [GI]: 3), 54 UC [female/male ratio: 
28/26; mean age at UC diagnosis: 36  years; disease extent: proc-
titis: 8, left-sided colitis: 24, extensive: 22] and 34 ileal pouch-anal 
anastomosis [IPAA] [female/male ratio: 18/16; mean age at UC diag-
nosis: 28 years] patients were enroled in the study. Demographics, 
duration, and characteristics of the diseases were recorded. The activ-
ities of CD, UC, and pouchitis were defined with the use of clinical, 
endoscopic, and histologic activity scores: Crohn’s Disease Activity 
Index [CDAI],8 Simplified Endoscopic Activity Score for Crohn’s 
Disease [SES-CD],9 and D’Haens score10 in case of CD, Mayo score 
[including partial and endoscopic subscore]11 and Riley score12 in the 
case of UC, and Pouchitis Disease Activity Index [PDAI]13 in the case 
of pouchitis, including the clinical, endoscopic, and histologic assess-
ments of patients with IPAA. The D’Haens score is a widely used 
scoring system for histologic abnormalities in CD mucosal biopsy 
specimens that combines active inflammatory changes and chronic 
architectural changes.14,15
Clinically active CD and UC were defined as CDAI > 150 points 
and pMayo score > 2.  Pouchitis was defined as PDAI > 7 points. 
SES-CD was defined as follows: inactive 0–3; mild 4–10; moderate 
11–19; and high ≥ 20. The patients’ demographic and clinical data 
are summarized in Table 1.
A colonoscopy was performed to evaluate the endoscopic activ-
ity in every patient. A  day before endoscopy, we requested that 
patients provide fecal samples. Blood samples were also obtained 
within 13 days before endoscopy.
2.3. Blood inflammatory markers, fecal CP and 
MMP-9 measurements
Routine laboratory methods were used to determine C-reactive pro-
tein, serum iron level, leukocyte number, hematocrit, hemoglobin 
levels, and the thrombocyte number.
Stool samples were obtained and stored at -20ºC until the deter-
mination of fecal CP and MMP-9 levels. For CP measurements, fecal 
specimens were thawed at 4ºC. CP level was quantified by use of 
enzyme-linked immunosorbent assay [Quantum Blue, Bühlmann 
Laboratories, Schönenbuch] according to the manufacturer’s 
Table 1. Demographic data and clinical characteristics of patients enroled in the study.
Characteristics Patients with CD [n = 50] Patients with UC [n = 54] Patients with ileal pouch-anal anastomosis [n = 34]
Mean age at onset [years] 30 36 28
Mean age at present [years] 38 43 40
Female/male 26/24 28/26 18/16
Location/extension
-Ileal 11 - -
-Colonic 15 - -
-Ileocolonic 24 - -
-Upper GI 3 - -
-Extensive - 22 -
-Left-sided - 24 -
-Proctitis - 8 -
Behavior
-Inflammatory 18 - -
-Stenosng 18 - -
-Penetrating 14 - -
Treatment
-No therapy 7 7 12
-Aminosalicylates 13 34 0
-Steroids 15 15 0
-Thiopurines 22 16 0
-Biologics 14 9 5
-Antibiotics 10 - 8
-Topical 2 12 2
CD, Crohn’s disease; UC, ulcerative colitis; GI, gastrointestinal.
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instructions. For MMP-9 measurements, 1 g of fecal sample was 
diluted, mixed, homogenized in 4 mL of ice-cold Tris-buffer [0.15 M 
NaCl + 20 mM Tris-HCl, pH 8.3] and then centrifuged. MMP-9 was 
also measured by quantitative enzyme-linked immunosorbent assay 
[R&D Systems, Abingdon, UK].
2.4. Colonoscopy, histologic examination
The participants underwent a colonoscopy performed by two 
experienced endoscopists [TM, ZSZ], either for activity symptoms 
or simply for a control examination, to evaluate the macroscopic 
inflammation of the colon or the pouch. Biopsies were taken for his-
tology during the endoscopy. Histologic variables were scored by a 
single pathologist [LT].
2.5. Statistical analyses
Correlations between fecal CP, MMP-9, and clinical, endoscopic and 
histologic activity scores were determined by analysis of variance 
[ANOVA]. The p-value of equal to or less than 0.05 was considered 
statistically significant. STATA 9 [StataCorp., TX, 2005] was used 
to analyze data. The cut-off levels, specificity, and sensitivity were 
calculated using the receiver operating characteristic [ROC] analysis. 
The cut-off level was calculated in the event that the value of the 
area under the ROC curve [AUC] was above 0.89, determined by 
the maximum value of Youden’s index [sensitivity + specificity-1].
2.6. Ethical considerations
The study protocol was approved by the Ethical Committee of the 
University of Szeged. All subjects provided written and informed 
consent to participation.
3. Results
3.1 Endoscopic and disease activity
Endoscopically active CD was revealed in 70.7% of the patients 
[26.9% mild, 14.6% moderate, 29.2% severe activity]. In UC, endo-
scopic activity was detected in 83.3% [27.8% mild, 14.8% moder-
ate, 40.7% severe]. The median value of SES-CD was 1 9interquartile 
range [[IQR]: 0 to 1.25) in patients with endoscopically inactive and 14 
[IQR: 8 to 24] in endoscopically active CD. In UC, the median value of 
the eMayo score was 0 in inactive and 2 [IQR: 1 to 3] in active patients. 
Pouchitis was detected in 50% of the patients; the median PDAI was 
10, and the median endoscopic subscore of PDAI was 3 [IQR: 2 to 4] 
in patients with pouchitis. The median values of the D’Haens and Riley 
scores in endoscopically active CD and UC patients were 8 [IQR: 7 
to 9] and 13 [IQR: 6.5 to 14], respectively. The median of the histologic 
score of pouchitis was 4 [IQR: 2 to 5]. The median of the CDAI was 
210 [IQR: 183 to 275] and 80 [IQR: 61 to 113] and the median of the 
pMayo score was 6 [IQR: 4 to 6] and 1 [IQR: 0 to 1] in the clinically 
active and inactive CD and UC patients, respectively.
3.2 Fecal CP and MMP-9 levels in CD patients
Median fecal CP was 500 µg/g and MMP-9 was 1.53 ng/mL in endo-
scopically active and 142 µg/g and 0.61 ng/mL in endoscopically inac-
tive patients, respectively. Median fecal CP concentrations were 650 
and 159 µg/g in patients with clinically active and inactive disease, 
respectively. Fecal CP concentration significantly correlated with the 
CDAI [p = 0.012]. However, no correlation was found between fecal 
CP concentration and SES-CD and histologic activity. Interestingly, 
after analyzing the data in view of the disease location, a significant 
correlation was revealed between fecal CP concentration and the 
CDAI in patients with a colonic location, as opposed to those with 
ileal and ileocolonic locations [p = 0.03 vs 0.5 and 0.06, respectively]. 
Median MMP-9 concentrations were 1.53 and 0.95 ng/mL in patients 
with active and inactive disease, respectively. Fecal MMP-9 did not 
correlate with the CDAI, nor with the SES-CD or the D’Haens score. 
The cut-off value could not be calculated since the AUC was well 
below 0.89. Correlation between fecal CP and MMP-9 showed bor-
derline significance [r = 0.39, p = 0.06]. Box-and-whisker plots for 
comparisons of fecal CP and MMP-9 medians between endoscopi-
cally active and non-active CD are shown in Figure 1.
3.3 Fecal CP and MMP-9 levels in UC patients
Median fecal CP was 300 µg/g and MMP-9 was 6.17 ng/mL in endo-
scopically active patients and 121 µg/g and 0.7 ng/mL in endoscopi-
cally inactive patients. Median fecal CP concentrations were 630 and 
146 µg/g in patients with clinically active and inactive disease, respec-
tively. Fecal CP correlated with the pMayo score [p = 0.05] and with the 
endoscopic Mayo score [p = 0.017], but not with the Riley score. The 
median MMP-9 concentrations were 6.62 and 0.81 ng/mL in patients 
with clinically active and inactive disease, respectively. Fecal MMP-9 
concentration correlated with clinical [p = 0.05], endoscopic and his-
tologic activity [p = 0.021 and p = 0.033, respectively] of the disease.
Although AUC could not reach the optimal 0.89 in the case of 
clinical nor in the case of endoscopic activity, the cut-off values could 
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Figure 1. Box-and-whisker plots for comparison of faecal CP and MMP-9 medians between endoscopically active and non-active CD
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be determined. The best cut-off of MMP-9 for the separation of clin-
ically active and inactive UC patients was 0.35 ng/mL, with a sensi-
tivity of 93% and a specificity of 63% [AUC = 0.74]. In the case of 
endoscopic activity, the optimal cut-off value proved to be 0.20 ng/
mL, with a sensitivity of 96% and a specificity of 75% [AUC = 0.806] 
[Figure 2]. Significant correlation was shown between fecal CP and 
MMP-9 levels [r = 0.73, p < 0.001]. Box-and-whisker plots for com-
parisons of fecal CP and MMP-9 medians between endoscopically 
active and non-active UC are shown in Figure 3.
3.4 Fecal CP and MMP-9 levels in patients with and 
without pouchitis
The median fecal CP concentration was 560 µg/g in patients with 
pouchitis and 96.5 µg/g in those without pouchitis. Statistically, the 
fecal CP correlated with the endoscopic and the histologic activity 
of pouchitis [p  =  0.0001, p  =  0.0002]. The median fecal MMP-9 
level was significantly higher in patients with [16.9 ng/mL] vs with-
out [1.34 ng/mL] pouchitis [p = 0.009]. Fecal MMP-9 also correlated 
with the endoscopic and histologic activity of patients with IPAA 
[p  =  0.011 and p  =  0.002, respectively]. For MMP-9, the cut-off 
value was revealed to be 0.24 ng/mL with a sensitivity and specific-
ity of 87% when examining both clinical and endoscopic activities 
[AUC  =  0.73 and 0.76, respectively] [Figure  4]. Significant corre-
lation was shown between fecal CP and MMP-9 levels [r  = 0.55, 
p = 0.009]. Box-and-whisker plots for comparisons of fecal CP and 
MMP-9 medians between endoscopically active and non-active 
IPAA patients are shown in Figure 5.
Correlation of fecal CP and MMP-9 with the clinical, endo-
scopic, and histologic activities in CD, UC, and pouchitis are sum-
marized in Table 2.
3.5. Correlation between the inflammatory laboratory 
parameters and different types of IBD and between 
the therapy and the correlations of fecal markers 
The median values of the CRP levels were 21 mg/L and 4.95 mg/L in 
clinically active and inactive CD, 8.6 mg/L and 2.15 mg/L in active and 
inactive UC, and 14.2 mg/L and 5 mg/L in patients with and without 
pouchitis, respectively. None of the laboratory markers correlated 
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significantly with CP and MMP-9 in CD and UC. However, in 
pouchitis a significant correlation was shown between both CP and 
MMP-9 and an elevated thrombocyte level [the median thrombocyte 
number in pouchitis: 305.5 g/L; p = 0.012 and p < 0.0002, respec-
tively]. In this cohort no association was shown between the therapy 
and the different correlations of fecal activity markers.
4. Discussion
This prospective study revealed significant correlation between 
fecal CP and the endoscopic activity of both UC and pouchitis. 
Strong association was revealed between fecal MMP-9 and clini-
cal, endoscopic, and histologic activities of both UC and pouchitis. 
The assessment of mucosal inflammation is known to be crucial in 
optimizing therapy in patients with IBD. Therefore, non-invasive 
markers, substituting for endoscopy, play a very important role in 
the follow-up of the patients. CP is a widely studied fecal activity 
marker in IBD. It proved to be effective for measuring intestinal 
inflammation, since the fecal concentration of CP is elevated both 
in CD and UC.1617,18 It appears to better reflect disease activity in 
UC than in CD, but fecal CP has not been found to be useful in 
distinguishing UC from CD.19,20 Very few data are available regard-
ing the role of fecal MMP-9 in diagnosing and predicting disease 
activity in IBD. MMPs partake in normal mucosal defence, as well 
as playing a role both in the evolution of the inflammatory processes 
and in the pathogenesis of inflammatory diseases.21 The study of 
Mäkitalo et al. revealed that serum levels of MMP-7, 8, and 9 are 
elevated in active IBD. In this study, MMP-7 was the most prominent 
marker that indicated a response to steroid therapy.22 Although the 
authors could not demonstrate alterations in MMP-9 levels follow-
ing the therapy, serum MMP-9 levels were elevated at baseline in 
patients with active IBD. There results did not support a role for 
serum MMP-9 as a marker for disease activity; however, a previous 
study confirmed an increased expression of MMP-9 in the mucosa 
of IBD patients.23 We previously confirmed that fecal MMP-9 is a 
reliable marker in separating UC and non-IBD patients, the higher 
levels being associated with more active disease.6 The first study on 
fecal MMP-9 in pediatric patients revealed that MMP-9 levels were 
Figure 4. ROC curves for faecal MMP-9 in pouchitis
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significantly lower in CD than in UC, whereas fecal CP was not use-
ful in differentiating pediatric UC and CD.7
Our study aimed to examine fecal MMP-9, a very new fecal activ-
ity marker for such indication, and whether the diagnostic accuracy 
of fecal MMP-9 is comparable with fecal CP. The patient samples 
included some taken from patients on maintenance treatment, who 
were referred for a colonoscopy. As our results showed, fecal CP was 
not useful in differentiating patients with CD and UC, as the values 
were comparable, confirming the above mentioned data. However, 
fecal MMP-9 showed a stronger association with UC than with CD, 
and also correlated solely with the clinical symptoms of pouchitis 
in our cohort. It is also important to note that fecal MMP-9 cor-
related not only with clinical activities of UC and pouchitis, but also 
with endoscopic and histologic activities, and thus can be useful for 
assessing mucosal inflammation during the follow-up period.
Whereas the diagnostic role of fecal CP in pouchitis has previ-
ously been examined in some studies, limited data are available on 
the role of MMP-9 in pouchitis. In the case of pediatric-onset UC 
patients, most pouch samples showed an increased expression of 
MMP-3 and MMP-7 in pouchitis.24 MMP-1 and MMP-2 concen-
trations in the mucosal biopsies were increased in pouchitis com-
pared with uninflamed pouches of patients with UC, in the study of 
Stallmach et al.25 Ulisse et al. revealed strong MMP-9 and MMP-2 
activities in the inflamed pouch, reduced after antibiotic treatment.26
Our results revealed that none of the routinely used laboratory 
activity markers correlates significantly with fecal CP and MMP-9 
levels in CD or UC. In pouchitis, fecal markers correlated only with 
thrombocytosis. Thrombocytosis is a common finding in IBD, sug-
gestive of active disease. Correlation between thrombocytosis and 
elevated fecal markers can be explained by the fact that both are 
potential markers of clinical disease activity. The level of fecal CP sig-
nificantly increased in clinically active colonic CD and UC, although 
fecal MMP-9 showed a significantly stronger correlation with the 
activity of UC than with that of CP, and this was the only marker 
correlating with the clinical symptoms of pouchitis. Significant cor-
relation was also shown between fecal CP and MMP-9 levels in 
patients with UC and pouchitis.
The authors are aware of the limitations of the study. The main 
limiting factor of the study is the relatively low number of enroled 
patients with regard to the different types of the studied disease; 
however, the accurately performed diagnostic and scoring proce-
dures and statistical analyses are strengths of this study.
5. Conclusion
This is the first study assessing the diagnostic accuracy of fecal 
MMP-9 in the different types of IBD. Our results showed that fecal 
MMP-9 has high sensitivity in the detection of endoscopically active 
UC and pouchitis, and these non-invasive methods help in assessing 
intestinal inflammation.
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